Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheeba K Thomas

Showing results (31-40 of 114) with videos related to

Pageof 12
Sort By:
Clinical Lung Cancer|April 28, 2006
Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access programSheeba K Thomas, Frank V Fossella, Diane Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2022
Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant MyelomaKrina K Patel, Jatin J Shah, Lei Feng, et al.
British Journal of Haematology|January 19, 2011
Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myelomaSally A Hunsucker, Valeria Magarotto, Deborah J Kuhn, et al.
European Journal of Haematology|January 17, 2016
Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvementTalha Badar, Amanda Megan Cornelison, Nina D Shah, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 1, 2010
Effect of long-term storage in TRIzol on microarray-based gene expression profilingWencai Ma, Michael Wang, Zhi-Qiang Wang, et al.
Blood Cancer Journal|February 10, 2021
Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow upElisabet E Manasanch, Chutima Kunacheewa, Catherine M Claussen, et al.
Blood Cancer Journal|December 3, 2025
Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapyKaran L Chohan, Lorenzo Gensini, Sherif Seif, et al.
Blood Cancer Journal|April 13, 2026
Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myelomaChristen M Dillard, Hans Lee, Nilesh Kalariya, et al.
International Journal of Radiation Oncology, Biology, Physics|December 9, 2023
Management and Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation TherapyPenny Fang, Chelsea C Pinnix, Susan Y Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2015
Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström MacroglobulinemiaIsere Kuiatse, Veerabhadran Baladandayuthapani, Heather Y Lin, et al.
Pageof 12

Showing results (31-40 of 114) with videos related to

Sort By:
Pageof 12
Clinical Lung Cancer|April 28, 2006
Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access programSheeba K Thomas, Frank V Fossella, Diane Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2022
Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant MyelomaKrina K Patel, Jatin J Shah, Lei Feng, et al.
British Journal of Haematology|January 19, 2011
Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myelomaSally A Hunsucker, Valeria Magarotto, Deborah J Kuhn, et al.
European Journal of Haematology|January 17, 2016
Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvementTalha Badar, Amanda Megan Cornelison, Nina D Shah, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 1, 2010
Effect of long-term storage in TRIzol on microarray-based gene expression profilingWencai Ma, Michael Wang, Zhi-Qiang Wang, et al.
Blood Cancer Journal|February 10, 2021
Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow upElisabet E Manasanch, Chutima Kunacheewa, Catherine M Claussen, et al.
Blood Cancer Journal|December 3, 2025
Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapyKaran L Chohan, Lorenzo Gensini, Sherif Seif, et al.
Blood Cancer Journal|April 13, 2026
Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myelomaChristen M Dillard, Hans Lee, Nilesh Kalariya, et al.
International Journal of Radiation Oncology, Biology, Physics|December 9, 2023
Management and Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation TherapyPenny Fang, Chelsea C Pinnix, Susan Y Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2015
Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström MacroglobulinemiaIsere Kuiatse, Veerabhadran Baladandayuthapani, Heather Y Lin, et al.
Pageof 12